STELLA PHARMA NEWS
SPM-011
December 10th, 2024

Observation Period Completed for Primary Endpoint – Phase II Clinical Trial in Patients with Angiosarcoma

We are pleased to announce the completion of the 90-day observation period for ……

READ MORE

September 25th, 2024

Orphan Drug Designation for Borofalan (10B) (SPM-011) as treatment of Recurrent Malignant Glioma and Recurrent Meningioma

Our product Borofalan (10B) (development code: SPM-011), which we are developin……

READ MORE

September 10th, 2024

Patient Enrollment Completed for Phase II Clinical Trial in Japan on Angiosarcoma

Stella Pharma completed the enrollment of patients for the domestic phase II do……

READ MORE

August 30th, 2024

Application for Orphan Drug Designation: Borofalan (10B) for Recurrent Malignant Glioma and Recurrent Meningioma

Stella Pharma announces that it has applied to the Japanese Ministry of Health,……

READ MORE

December 25th, 2023

Orphan Drug designation for Borofalan (10B) (SPM-011) as treatment of Cutaneous Angiosarcoma

Angiosarcoma is a kind of cancer that is derived from vascular endothelial cell……

READ MORE